Universidad Peruana Cayetano Heredia

Using government data to understand the use and availability of medicines for hypertension and diabetes: lessons from Peru

Mostrar el registro sencillo del ítem

dc.contributor.author Tenorio Mucha, Janeth Marilyn
dc.contributor.author Lazo Porras, María de los Ángeles
dc.contributor.author Zafra-Tanaka, Jessica Hanae
dc.contributor.author Ewen, M.
dc.contributor.author Beran, D.
dc.date.accessioned 2022-12-14T14:25:34Z
dc.date.available 2022-12-14T14:25:34Z
dc.date.issued 2022
dc.identifier.uri https://hdl.handle.net/20.500.12866/12890
dc.description.abstract Background: Regular measurement of the availability and use of key medicines for non-communicable diseases allows the tracking of progress to achieve equitable access to medicines. Using a country-level public sector monitoring system for medicine supply, we aim to evaluate the availability and use of losartan 50 mg tablets and metformin 850 mg tablets between 2015 and 2020 investigating the impact of different policy changes and the COVID-19 pandemic. Methods: Data from the Peruvian National System of Medicine Supply were analyzed using an interrupted time series analysis with known and unknown structural breaks. The outcomes assessed were medicine use (monthly doses dispensed at facilities over time) and medicine availability (proportion of facilities that reported having the medicine available). Results: The use of losartan and metformin at the primary level of care had a linear increasing trend over the period of analysis. In secondary and tertiary levels of care, there were no increases but some significant level and trend changes of doses dispensed at different times between 2017 to 2019, but none were related to the change of procurement procedures. At all levels of care, the COVID-19 onset in April 2020 caused an abrupt drop in doses dispensed especially at the primary level. Regarding availability, we found an increasing linear trend in the primary level of care for both medicines. In secondary and tertiary levels of care, the availability fluctuated between 40 and 95%. The onset of the COVID-19 pandemic did not significantly impact medicine availability, except for losartan in the tertiary level of care. Conclusion: The availability and proper dispensing of first-line medicines for hypertension and diabetes is an essential factor for sustainable and equitable treatment. Health care systems need to be prepared for forecasting the increasing demand of medicines for chronic diseases, but also to maintain effective medicine supply chains during humanitarian crisis like pandemics. en_US
dc.language.iso eng
dc.publisher Springer
dc.relation.ispartofseries Journal of Pharmaceutical Policy and Practice
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject Essential drugs en_US
dc.subject Drug utilization en_US
dc.subject Losartan en_US
dc.subject Metformin en_US
dc.subject Segmented regression en_US
dc.subject Time series en_US
dc.title Using government data to understand the use and availability of medicines for hypertension and diabetes: lessons from Peru en_US
dc.type info:eu-repo/semantics/article
dc.identifier.doi https://doi.org/10.1186/s40545-022-00481-5
dc.relation.issn 2052-3211


Ficheros en el ítem

Ficheros Tamaño Formato Ver

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

info:eu-repo/semantics/restrictedAccess Excepto si se señala otra cosa, la licencia del ítem se describe como info:eu-repo/semantics/restrictedAccess

Buscar en el Repositorio


Listar

Panel de Control

Estadísticas